PDS Biotech to Participate at 33rd Annual Oppenheimer Healthcare Conference

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/20/2026

1. MRNA
2. KEYS
3. KLAR
4. MRK
5. PANW

6. HD
7. UBER
8. SPY
9. DVLT
10. NBIS

Get Alerts PDSB Hot Sheet

Price: $0.20 -4.76%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

FLORHAM PARK, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer, will present at the 33rd Annual Oppenheimer Healthcare Conference being held virtually on March 13-15, 2023.

Oppenheimer Conference Presentation Date: Tuesday, March 14, 2023Time: 8:00 AM ETInvestors can register for the webcast here

Following the conference, a webcast replay of the presentation will be available on the Investor section of the company’s website, PDS Biotechnology.

About PDS Biotechnology PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune®, PDS0301, and Infectimune™ T cell-activating platforms. We believe our targeted Versamune® and PDS0301 based candidates have the potential to overcome the limitations of current immunotherapy approaches through the activation of the right type, quantity and potency of T cells. To date, our lead Versamune® clinical candidate, PDS0101, has demonstrated the ability to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV16-associated cancers in multiple Phase 2 clinical trials. Our Infectimune™ based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Investor Contacts:Deanne RandolphPDS BiotechPhone: +1 (908) 517-3613Email: [email protected]

Rich CockrellCG CapitalPhone: +1 (404) 736-3838Email: [email protected]

Media Contacts: Tiberend Strategic Advisors, Inc.Dave Schemelia Phone: +1 (609) 468-9325 [email protected]

Bill Borden Phone: +1 (732) 910-1620 [email protected]